Yoshinaga Okugawa

List of Publications by Year
in descending order

121 papers	6,273 citations	66343 42 h-index	76900 74 g-index
121 all docs	121 docs citations	121 times ranked	10227 citing authors

#	Article	IF	Citations
1	Novel evidence for m6A methylation regulators as prognostic biomarkers and FTO as a potential therapeutic target in gastric cancer. British Journal of Cancer, 2022, 126, 228-237.	6.4	25
2	Investigation of miRNA expression profiles using cohort samples reveals potential early detectability of colorectal cancers by serum miRâ€'26aâ€'5p before clinical diagnosis. Oncology Letters, 2022, 23, 87.	1.8	4
3	Clinical Relevance of Myopenia and Myosteatosis in Colorectal Cancer. Journal of Clinical Medicine, 2022, 11, 2617.	2.4	7
4	The advanced lung cancer inflammation index predicts outcomes in patients with Crohnâ€™s disease after surgical resection. Colorectal Disease, 2021, 23, 84-93.	1.4	5
5	Prognostic Potential of Lymphocyteâ€"C-Reactive Protein Ratio in Patients with Rectal Cancer Receiving Preoperative Chemoradiotherapy. Journal of Gastrointestinal Surgery, 2021, 25, 492-502.	1.7	24
6	Clinical significance of advanced lung cancer inflammation index, a nutritional and inflammation index, in gastric cancer patients after surgical resection: A propensity score matching analysis. Clinical Nutrition, 2021, 40, 1130-1136.	5.0	23
7	Clinical implications of the preoperative lymphocyte C-reactive protein ratio in esophageal cancer patients. Surgery Today, 2021, 51, 745-755.	1.5	23
8	Cumulative perioperative lymphocyte/C-reactive protein ratio as a predictor of the long-term outcomes of patients with colorectal cancer. Surgery Today, 2021, 51, 1906-1917.	1.5	9
9	Profiling plasma angiogenesis factors after use of biologics in metastatic colorectal cancer (mCRC): Update results from GI-SCREEN CRC Ukit study.. Journal of Clinical Oncology, 2021, 39, 3529-3529.	1.6	1
10	Modified intramuscular adipose tissue content as a feasible surrogate marker for malnutrition in gastrointestinal cancer. Clinical Nutrition, 2021, 40, 2640-2653.	5.0	10
11	Antitumor effects of Andrographis via ferroptosisâ€'associated genes in gastric cancer. Oncology Letters, 2021, 22, 523.	1.8	17
12	A blood-based transcriptomic signature for noninvasive diagnosis of gastric cancer. British Journal of Cancer, 2021, 125, 846-853.	6.4	5
13	HER2-positive adenocarcinoma arising from heterotopic pancreas tissue in the duodenum: A case report. World Journal of Gastroenterology, 2021, 27, 4738-4745.	3.3	4
14	Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer. Clinical Nutrition, 2020, 39, 1209-1217.	5.0	90
15	Crohnâ€™s-Like Lymphoid Reaction is Associated with Oncological Prognosis and Nutritional Status in Patients with Pathological Stage II/III Gastric Cancer. Annals of Surgical Oncology, 2020, 27, 259-267.	1.5	4
16	Modified neutrophil-platelet score as a promising marker for stratified surgical and oncological outcomes of patients with gastric cancer. Surgery Today, 2020, 50, 223-231.	1.5	5
17	Neutrophil priming as a risk factor for surgical site infection in patients with colon cancer treated by laparoscopic surgery. BMC Surgery, 2020, 20, 5.	1.3	2
18	Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer. Annals of Surgery, 2020, 272, 342-351.	4.2	167

#	Article	IF	Citations
19	Fusobacterium nucleatum infection correlates with two types of microsatellite alterations in colorectal cancer and triggers DNA damage. Gut Pathogens, 2020, 12, 46.	3.4	22
20	Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition. Cancer Science, 2020, 111, 3962-3969.	3.9	18
21	Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients. Cancer Immunology, Immunotherapy, 2020, 69, 2533-2546.	4.2	31
22	Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer. Gut, 2020, 69, 1818-1831.	12.1	80
23	Genetic influence of cytokine polymorphisms on the clinical outcome of Japanese gastrointestinal cancer patients in palliative care. Oncology Letters, 2019, 17, 623-629.	1.8	3
24	Rac GTPase-Activating Protein 1 (RACGAP1) as an Oncogenic Enhancer in Esophageal Carcinoma. Oncology, 2019, 97, 155-163.	1.9	10
25	Clinical Implications of Pretreatment: Lymphocyte-to-Monocyte Ratio in Patients With Rectal Cancer Receiving Preoperative Chemoradiotherapy. Diseases of the Colon and Rectum, 2019, 62, 171-180.	1.3	18
26	Circulating miR–203 derived from metastatic tissues promotes myopenia in colorectal cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 536-548.	7.3	57
27	Clinical significance and biological role of L1 cell adhesion molecule in gastric cancer. British Journal of Cancer, 2019, 121, 1058-1068.	6.4	20
28	Comment on "Prognostic Nutritional Index, Tumor-infiltrating Lymphocytes, and Prognosis in Patients With Esophageal Cancer" Annals of Surgery, 2019, 270, e104-e105.	4.2	4
29	Identification of Predictors of Recurrence in Patients with Lower Rectal Cancer Undergoing Neoadjuvant Chemotherapy: A Direct Comparison of Short-Course and Long-Course Chemoradiotherapy. Oncology, 2019, 96, 70-78.	1.9	1
30	Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer. Cancer Letters, 2019, 444, 127-135.	7.2	40
31	Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression. Annals of Surgical Oncology, 2019, 26, 876-883.	1.5	74
32	Close Relationship Between Immunological/Inflammatory Markers and Myopenia and Myosteatosis in Patients With Colorectal Cancer: A Propensity Score Matching Analysis. Journal of Parenteral and Enteral Nutrition, 2019, 43, 508-515.	2.6	31
33	Risk factors and measures of pulmonary complications after thoracoscopic esophagectomy for esophageal cancer. Surgery Today, 2019, 49, 176-186.	1.5	32
34	Re: Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study. Gut, 2019, 68, 575.1-575.	12.1	4
35	Polymorphisms in and have no significant effect on plasma carnitine levels in Japanese cancer patients. Nagoya Journal of Medical Science, 2019, 81, 477-487.	0.3	0
36	Feasibility of Assessing Prognostic Nutrition Index in Patients With Rectal Cancer Who Receive Preoperative Chemoradiotherapy. Journal of Parenteral and Enteral Nutrition, 2018, 42, 998-1007.	2.6	31

#	Article	IF	Citations
37	A RNA-Sequencing approach for the identification of novel long non-coding RNA biomarkers in colorectal cancer. Scientific Reports, 2018, 8, 575.	3.3	80
38	Prognostic impact of sarcopenia and its correlation with circulating miR-21 in colorectal cancer patients. Oncology Reports, 2018, 39, 1555-1564.	2.6	30
39	Enhanced AZIN1 RNA editing and overexpression of its regulatory enzyme ADAR1 are important prognostic biomarkers in gastric cancer. Journal of Translational Medicine, 2018, 16, 366.	4.4	48
40	MicroRNAs as potential liquid biopsy biomarkers in colorectal cancer: A systematic review. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 274-282.	7.4	68
41	Reply. Gastroenterology, 2018, 154, 2274-2275.	1.3	0
42	Clinical Impact of Muscle Quantity and Quality in Colorectal Cancer Patients: A Propensity Score Matching Analysis. Journal of Parenteral and Enteral Nutrition, 2018, 42, 1322-1333.	2.6	35
43	Colony-stimulating factor-1 and colony-stimulating factor-1 receptor co-expression is associated with disease progression in gastric cancer. International Journal of Oncology, 2018, 53, 737-749.	3.3	17
44	Clinical Impact of Preoperative Albumin-Globulin Ratio in Patients with Rectal Cancer Treated with Preoperative Chemoradiotherapy. Oncology, 2018, 95, 270-280.	1.9	7
45	AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer. JCI Insight, 2018, 3, .	5.0	91
46	Comprehensive analysis identifying aberrant DNA methylation in rectal mucosa from ulcerative colitis patients with neoplasia. Oncotarget, 2018, 9, 33149-33159.	1.8	6
47	Clinical Burden of Modified Glasgow Prognostic Scale in Colorectal Cancer. Anticancer Research, 2018, 38, 1599-1610.	1.1	14
48	Polymorphisms in folic acid metabolism genes do not associate with cancer cachexia in Japanese gastrointestinal patients. Nagoya Journal of Medical Science, 2018, 80, 529-539.	0.3	1
49	Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer. Gut, 2017, 66, 654-665.	12.1	185
50	Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer. Gut, 2017, 66, 107-117.	12.1	110
51	Emerging Role of MicroRNAs as Liquid Biopsy Biomarkers in Gastrointestinal Cancers. Clinical Cancer Research, 2017, 23, 2391-2399.	7.0	103
52	Clinical burden of preoperative albumin-globulin ratio in esophageal cancer patients. American Journal of Surgery, 2017, 214, 891-898.	1.8	46
53	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biology, 2017, 18, 98.	8.8	97
54	FOXD3 Regulates CSC Marker, DCLK1-S, and Invasive Potential: Prognostic Implications in Colon Cancer. Molecular Cancer Research, 2017, 15, 1678-1691.	3.4	27

#	Article	IF	Citations
55	A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients With Ulcerative Colitis-Associated ColorectalÂCancer. Gastroenterology, 2017, 153, 1634-1646.e8.	1.3	54
56	Fish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia. Scientific Reports, 2017, 7, 4826.	3.3	57
57	Exportin-5 Functions as an Oncogene and a Potential Therapeutic Target in Colorectal Cancer. Clinical Cancer Research, 2017, 23, 1312-1322.	7.0	34
58	Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis. Clinical Cancer Research, 2017, 23, 1323-1333.	7.0	67
59	Successful identification of a predictive biomarker for lymph node metastasis in colorectal cancer using a proteomic approach. Oncotarget, 2017, 8, 106935-106947.	1.8	21
60	Objective Predictive Score as a Feasible Biomarker for Short-term Survival in Terminally Ill Patients with Cancer. Anticancer Research, 2017, 37, 267-276.	1.1	8
61	Clinical Significance of C-Reactive Protein-to- Albumin Ratio with Rectal Cancer Patient Undergoing Chemoradiotherapy Followed by Surgery. , 2017, 37, 5797-5804.		23
62	A Case of Metastatic Axillary Adenocarcinoma of Unknown Primary Site Suggestive of Granulocyte-colony Stimulating Factor Production. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.g	
63	FOXM1 and FOXQ1 Are Promising Prognostic Biomarkers and Novel Targets of Tumor-Suppressive miR-342 in Human Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4947-4957.	7.0	65
64	Elevated serum concentration of monocyte chemotactic protein 4 (MCP-4) as a novel non-invasive prognostic and predictive biomarker for detection of metastasis in colorectal cancer. Journal of Surgical Oncology, 2016, 114, 483-489.	1.7	7
65	Novel evidence for an oncogenic role of microRNA-21 in colitis-associated colorectal cancer. Gut, 2016, 65, 1470-1481.	12.1	120
66	Microsatellite Alterations With Allelic Loss at 9p24.2 SignifyÂLess-Aggressive Colorectal Cancer Metastasis. Gastroenterology, 2016, 150, 944-955.	1.3	34
67	Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer. Oncotarget, 2016, 7, 16158-16171.	1.8	135
68	A Case of Iliacus Muscle Hematoma Associated with Heparin Bridging for Surgical Resection of Gastric Cancer. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2016, 77, 1585-1589.	0.0	0
69	Efficacy and safety of laparoscopic surgery in elderly patients with colorectal cancer. Molecular and Clinical Oncology, 2015, 3, 897-901.	1.0	12
70	Epigenetic changes and alternate promoter usage by human colon cancers for expressing DCLK1-isoforms: Clinical Implications. Scientific Reports, 2015, 5, 14983.	3.3	57
71	Elevated Platelet Count as Predictor of Recurrence in Rectal Cancer Patients Undergoing Preoperative Chemoradiotherapy Followed by Surgery. International Surgery, 2015, 100, 199-207.	0.1	41
72	Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia. Clinical Cancer Research, 2015, 21, 4234-4242.	7.0	128

#	Article	IF	Citations
73	RacGAP1 expression, increasing tumor malignant potential, as a predictive biomarker for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis, 2015, 36, 346-354.	2.8	93
74	Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis, 2015, 36, 355-367.	2.8	200
75	Identification of a Metastasis-Specific MicroRNA Signature in Human Colorectal Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	139
76	Immunodeficiency and Autoimmune Enterocolopathy Linked to NFAT5 Haploinsufficiency. Journal of Immunology, 2015, 194, 2551-2560.	0.8	32
77	Epigenetic Alterations in Colorectal Cancer: EmergingÂBiomarkers. Gastroenterology, 2015, 149, 1204-1225.e12.	1.3	561
78	Novel Evidence for Curcumin and Boswellic Acidâ€"Induced Chemoprevention through Regulation of miR-34a and miR-27a in Colorectal Cancer. Cancer Prevention Research, 2015, 8, 431-443.	1.5	102
79	Serum angiopoietin-like protein 2 as a potential biomarker for diagnosis, early recurrence and prognosis in gastric cancer patients. Carcinogenesis, 2015, 36, bgv139.	2.8	23
80	MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1. Gut, 2015, 64, 203-214.	12.1	133
81	Clinical significance of RacGAP1 expression at the invasive front of gastric cancer. Gastric Cancer, 2015, 18, 84-92.	5.3	73
82	Brain-Derived Neurotrophic Factor (BDNF)-Induced Tropomyosin-Related Kinase B (Trk B) Signaling Is a Potential Therapeutic Target for Peritoneal Carcinomatosis Arising from Colorectal Cancer. PLoS ONE, 2014, 9, e96410.	2.5	62
83	In Vivo Characterization of Neutrophil Extracellular Traps in Various Organs of a Murine Sepsis Model. PLoS ONE, 2014, 9, e111888.	2.5	132
84	Elevated Serum Angiopoietin-like Protein 2 Correlates with the Metastatic Properties of Colorectal Cancer: A Serum Biomarker for Early Diagnosis and Recurrence. Clinical Cancer Research, 2014, 20, 6175-6186.	7.0	40
85	Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. Carcinogenesis, 2014, 35, 2731-2739.	2.8	242
86	DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochemical and Biophysical Research Communications, 2014, 455, 43-57.	2.1	139
87	An update on microRNAs as colorectal cancer biomarkers: where are we and whatâ€™s next?. Expert Review of Molecular Diagnostics, 2014, 14, 999-1021.	3.1	48
88	In vivo optical imaging of cancer metastasis using multiphoton microscopy: a short review. American Journal of Translational Research (discontinued), 2014, 6, 179-87.	0.0	22
89	Significant correlation between LKB1 and LGR5 gene expression and the association with poor recurrence-free survival in rectal cancer after preoperative chemoradiotherapy. Journal of Cancer Research and Clinical Oncology, 2013, 139, 131-138.	2.5	29
90	Smad interacting protein 1 (SIP1) is associated with peritoneal carcinomatosis in intestinal type gastric cancer. Clinical and Experimental Metastasis, 2013, 30, 417-429.	3.3	21

#	Article	IF	Citations
91	Macrophage inflammatory protein‑3 alpha (MIP‑3a) Is a novel serum prognostic marker in patients with colorectal cancer. Journal of Surgical Oncology, 2013, 107, 160-166.	1.7	24
92	Prognostic Significance of a Systemic Inflammatory Response in Patients Undergoing Multimodality Therapy for Advanced Colorectal Cancer. Oncology, 2013, 84, 100-107.	1.9	56
93	Loss of the metastasis suppressor gene KiSS1 is associated with lymph node metastasis and poor prognosis in human colorectal cancer. Oncology Reports, 2013, 30, 1449-1454.	2.6	24
94	C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery. Anticancer Research, 2013, 33, 5065-74.	1.1	49
95	In vivo real-time imaging of chemotherapy response on the liver metastatic tumor microenvironment using multiphoton microscopy. Oncology Reports, 2012, 28, 1822-1830.	2.6	29
96	The prognostic value of KRAS mutations in patients with colorectal cancer. Oncology Reports, 2012, 28, 1579-1584.	2.6	23
97	Clinical Significance of Serum Soluble E-cadherin in Colorectal Carcinoma. Journal of Surgical Research, 2012, 175, e67-e73.	1.6	39
98	CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. European Journal of Cancer, 2012, 48, 2244-2251.	2.8	102
99	Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy. Oncology Reports, 2012, 28, 855-861.	2.6	23
100	Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. Surgery Today, 2012, 42, 460-469.	1.5	41
101	Intravital dual‑colored visualization of colorectal liver metastasis in living mice using two photon laser scanning microscopy. Microscopy Research and Technique, 2012, 75, 307-315.	2.2	26
102	Correlation of MACC1 and MET expression in rectal cancer after neoadjuvant chemoradiotherapy. Anticancer Research, 2012, 32, 1527-31.	1.1	27
103	Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy. Oncology Reports, 2011, 26, 1069-74.	2.6	21
104	DPEP1, expressed in the early stages of colon carcinogenesis, affects cancer cell invasiveness. Journal of Gastroenterology, 2011, 46, 153-163.	5.1	37
105	KAP1 Is Associated With Peritoneal Carcinomatosis in Gastric Cancer. Annals of Surgical Oncology, 2010, 17, 821-828.	1.5	99
106	Stromal CXCR4 and CXCL12 Expression is Associated with Distant Recurrence and Poor Prognosis in Rectal Cancer After Chemoradiotherapy. Annals of Surgical Oncology, 2010, 17, 2051-2058.	1.5	48
107	Intravital imaging of DSS-induced cecal mucosal damage in GFP-transgenic mice using two-photon microscopy. Journal of Gastroenterology, 2010, 45, 544-553.	5.1	48
108	Immunohistochemical features of CD133 expression: Association with resistance to chemoradiotherapy in rectal cancer. Oncology Reports, 2010, 24, 345-50.	2.6	43

#	Article	IF	Citations
109	Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. Oncology Reports, 2009, 22, 709-17.	2.6	43
110	Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. International Journal of Cancer, 2009, 125, 1657-1662.	5.1	69
111	Ovarian autoamputation in a neonate: a case report with literature review. Pediatric Surgery International, 2009, 25, 655-658.	1.4	25
112	Correlation of CD133, OCT4, and SOX2 in Rectal Cancer and Their Association with Distant Recurrence After Chemoradiotherapy. Annals of Surgical Oncology, 2009, 16, 3488-3498.	1.5	283
113	Serum Level of Soluble Vascular Cell Adhesion Molecule 1 Is a Valuable Prognostic Marker in Colorectal Carcinoma. Diseases of the Colon and Rectum, 2009, 52, 1330-1336.	1.3	15
114	Decreased Expression of Monocyte Chemoattractant Protein-1 Predicts Poor Prognosis Following Curative Resection of Colorectal Cancer. Diseases of the Colon and Rectum, 2008, 51, 1800-1805.	1.3	13
115	Preoperative C–reactive protein as a prognostic and therapeutic marker for colorectal cancer. Journal of Surgical Oncology, 2008, 98, 540-544.	1.7	110
116	Soluble Intercellular Adhesion Molecule-1 as a Prognostic Marker for Stage II Colorectal Cancer Patients. Annals of Surgical Oncology, 2008, 15, 1617-1624.	1.5	22
117	Increased Plasma Thrombomodulin as a Vascular Endothelial Cell Marker in Patients With Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 5-9.	1.7	26
118	Plasma Levels of Total Plasminogen Activator Inhibitor-I (PAI-I) and tPA/PAI-1 Complex in Patients With Disseminated Intravascular Coagulation and Thrombotic Thrombocytopenic Purpura. Clinical and Applied Thrombosis/Hemostasis, 2001, 7, 229-233.	1.7	37
119	Decreased tissue factor and tissue-plasminogen activator antigen in relapsed acute promyelocytic leukemia. American Journal of Hematology, 2000, 64, 145-150.	4.1	15
120	Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states. American Journal of Hematology, 2000, 65, 35-40.	4.1	28
121	Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation. American Journal of Hematology, 2000, 65, 210-214.	4.1	8